Education
About Us
Working with TipRanks
Follow Us
Sonnet BioTherapeutics Holdings (SONN)
NASDAQ:SONN
RESEARCH TOOLSreports
Total Valuation
Sonnet BioTherapeutics Holdings has a market cap or net worth of $3.70M. The enterprise value is -$826.45K.
Market Cap$3.70M
Enterprise Value-$826.45K
Share Statistics
Sonnet BioTherapeutics Holdings has 3,165,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,165,810
Owned by Insiders0.86%
Owned by Institutions4.36%
Financial Efficiency
Sonnet BioTherapeutics Holdings’s return on equity (ROE) is 15.31 and return on invested capital (ROIC) is 3339.05%.
Return on Equity (ROE)15.31
Return on Assets (ROA)-2.68
Return on Invested Capital (ROIC)3339.05%
Return on Capital Employed (ROCE)26.98
Revenue Per Employee1.43K
Profits Per Employee-572.09K
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sonnet BioTherapeutics Holdings is -0.59. Sonnet BioTherapeutics Holdings’s PEG ratio is 0.01.
PE Ratio-0.59
PS Ratio0.00
PB Ratio0.64
Price to Fair Value-9.02
Price to FCF-0.47
Price to Operating Cash Flow-0.31
PEG Ratio0.01
Income Statement
In the last 12 months, Sonnet BioTherapeutics Holdings had revenue of 18.63K and earned -7.44M in profits. Earnings per share was -11.35.
Revenue18.63K
Gross Profit18.63K
Operating Income-11.85M
Pretax Income-7.44M
Net Income-7.44M
EBITDA-11.77M
Earnings Per Share (EPS)-11.35
Cash Flow
In the last 12 months, operating cash flow was -8.43M and capital expenditures -12.00K, giving a free cash flow of -8.44M billion.
Operating Cash Flow-8.43M
Free Cash Flow-8.44M
Free Cash Flow per Share-2.67
Dividends & Yields
Sonnet BioTherapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change-91.03%
50-Day Moving Average1.29
200-Day Moving Average2.92
Relative Strength Index (RSI)41.54
Average Volume (3m)38.05K
Important Dates
Sonnet BioTherapeutics Holdings upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 20, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Sonnet BioTherapeutics Holdings as a current ratio of 0.66, with Debt / Equity ratio of 2.75%
Current Ratio0.66
Quick Ratio0.66
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sonnet BioTherapeutics Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sonnet BioTherapeutics Holdings EV to EBITDA ratio is -0.37, with an EV/FCF ratio of -0.51.
EV to Sales234.35
EV to EBITDA-0.37
EV to Free Cash Flow-0.51
EV to Operating Cash Flow-0.51
Balance Sheet
Sonnet BioTherapeutics Holdings has $4.86M in cash and marketable securities with $110.96K in debt, giving a net cash position of -$4.75M billion.
Cash & Marketable Securities$4.86M
Total Debt$110.96K
Net Cash-$4.75M
Net Cash Per Share-$1.50
Tangible Book Value Per Share-$0.74
Margins
Gross margin is -316.71%, with operating margin of -63617.91%, and net profit margin of -39929.30%.
Gross Margin-316.71%
Operating Margin-63617.91%
Pretax Margin-39929.30%
Net Profit Margin-39929.30%
EBITDA Margin-63171.67%
EBIT Margin-63617.91%
Analyst Forecast
The average price target for Sonnet BioTherapeutics Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast978.39%
EPS Growth Forecast69.65%